Sex Differences in Risk for Alcohol Abuse

Status Completed

Clinical Trial Summary

This study will determine the neural and hormonal mechanisms underlying sex differences in sensitivity to the disinhibiting effects of alcohol in heavy drinkers.

Clinical Trial Description

Alcohol abuse inflicts enormous physical, emotional, and financial burdens on the individual and society at large. Knowing who is at risk for alcohol abuse, and why, is crucial for the development of effective prevention and treatment strategies. Alcohol abuse has been traditionally considered a male-oriented problem and as a consequence research on risk factors specific to women has been minimal. However, the sex gap in substance abuse is closing rapidly, and findings from both animal and human studies suggest that females are actually more vulnerable to drug use than males. As such, there is an urgent need to identify sex differences in risk factors for alcohol abuse in order to develop sex-specific prevention and treatment efforts. One clear candidate risk factor is poor inhibitory control, both in terms of baseline levels of inhibition and sensitivity to the disinhibiting effects of alcohol. Recent studies suggest that sex hormones affect inhibitory control in drug-free individuals, potentially contributing to sex differences in baseline levels of inhibition. However, the degree to which fluctuations in sex hormones influence sex differences in inhibition-related brain function in sober and intoxicated individuals is not known. The proposed project will determine the neural and hormonal mechanisms underlying sex differences in sensitivity to the disinhibiting effects of alcohol in heavy drinkers. The overall objective of the research is to identify hormonal determinants of alcohol effects on brain activation during response inhibition (BARI) in young adult female and male drinkers. BARI will be assessed using functional magnetic resonance imaging (fMRI) during performance of the stop signal task. This task reliably activates right-lateralized prefrontal regions implicated in inhibitory control. This study will assess BARI during IV alcohol (60mg%) and saline infusion in women during the early follicular and mid-luteal phases and in men at matched intervals. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04543942
Study type	Interventional
Source	University of Kentucky
Contact
Status	Completed
Phase	N/A
Start date	November 1, 2019
Completion date	May 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05246202` - Personalized Feedback Intervention for Latinx Drinkers With Anxiety	N/A
Completed	`NCT03165942` - Neuroendocrine Response to Oral Alcohol Administration	Phase 1
Recruiting	`NCT05343039` - Technology Enhanced Adolescent Mental Health (TEAM)	N/A
Active, not recruiting	`NCT04070521` - EEG Monitoring in the Emergency Department
Completed	`NCT03169244` - Buproprion for Binge Drinking	Phase 2
Completed	`NCT05036499` - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain	N/A
Recruiting	`NCT04368416` - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Not yet recruiting	`NCT04557631` - Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
Terminated	`NCT00890149` - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults	Phase 2
Completed	`NCT02179749` - Mifepristone Treatment of Alcohol Use Disorder	Phase 2
Completed	`NCT02448134` - A Community-Based Strategy for Preventing Underage Drinking	N/A
Completed	`NCT02681406` - Smartphone Based Continuing Care for Alcohol	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Withdrawn	`NCT01796158` - Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use	N/A
Completed	`NCT01553136` - Varenicline Treatment of Alcohol Dependence in Smokers	Phase 2
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Withdrawn	`NCT01511679` - Brain-imaging and Adolescent Neuroscience Consortium	N/A
Withdrawn	`NCT01275391` - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use	Phase 1/Phase 2
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Completed	`NCT00907309` - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.